BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38527406)

  • 1. Electrochemiluminescence biosensor for specific detection of pancreatic ductal carcinoma through dual targeting of MUC1 and miRNA-196a.
    Chen Y; Ye Z; Ma M; Yang J; Liu R; Zhang Y; Ma P; Song D
    Biosens Bioelectron; 2024 Jun; 254():116241. PubMed ID: 38527406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
    Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
    Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
    Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasensitive electrochemiluminescence biosensing platform for miRNA-21 and MUC1 detection based on dual catalytic hairpin assembly.
    Li J; Liu J; Bi Y; Sun M; Bai J; Zhou M
    Anal Chim Acta; 2020 Apr; 1105():87-94. PubMed ID: 32138930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration.
    Chhieng DC; Benson E; Eltoum I; Eloubeidi MA; Jhala N; Jhala D; Siegal GP; Grizzle WE; Manne U
    Cancer; 2003 Dec; 99(6):365-71. PubMed ID: 14681945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
    Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
    Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated expression level of microRNA-196a is predictive of intestinal-type intraductal papillary mucinous neoplasm of the pancreas.
    Aso T; Ohtsuka T; Tamura K; Ideno N; Kono H; Nagayoshi Y; Ohuchida K; Ueda J; Takahata S; Shindo K; Aishima S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2014 Apr; 43(3):361-6. PubMed ID: 24622064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
    Xu X; Bhandari K; Xu C; Morris K; Ding WQ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis.
    Kong X; Du Y; Wang G; Gao J; Gong Y; Li L; Zhang Z; Zhu J; Jing Q; Qin Y; Li Z
    Dig Dis Sci; 2011 Feb; 56(2):602-9. PubMed ID: 20614181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice.
    Yokoyama S; Kitamoto S; Higashi M; Goto Y; Hara T; Ikebe D; Yamaguchi T; Arisaka Y; Niihara T; Nishimata H; Tanaka S; Takaori K; Batra SK; Yonezawa S
    PLoS One; 2014; 9(4):e93760. PubMed ID: 24714692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Versatile and Ultrasensitive Electrochemiluminescence Biosensor for Biomarker Detection Based on Nonenzymatic Amplification and Aptamer-Triggered Emitter Release.
    Nie Y; Yuan X; Zhang P; Chai YQ; Yuan R
    Anal Chem; 2019 Mar; 91(5):3452-3458. PubMed ID: 30667212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
    Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
    Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.
    Luan Z; Morimoto Y; Fushimi A; Yamashita N; Suo W; Bhattacharya A; Hagiwara M; Jin C; Kufe D
    Carcinogenesis; 2022 Feb; 43(1):67-76. PubMed ID: 34657147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
    Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
    BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
    Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
    Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma.
    Wang S; Chen X; Tang M
    Tumour Biol; 2014 Sep; 35(9):9101-9. PubMed ID: 25027396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.